JP2011514355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011514355A5 JP2011514355A5 JP2010550647A JP2010550647A JP2011514355A5 JP 2011514355 A5 JP2011514355 A5 JP 2011514355A5 JP 2010550647 A JP2010550647 A JP 2010550647A JP 2010550647 A JP2010550647 A JP 2010550647A JP 2011514355 A5 JP2011514355 A5 JP 2011514355A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- patient
- composition
- platinum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 39
- 239000000203 mixture Substances 0.000 claims 35
- 229940123237 Taxane Drugs 0.000 claims 27
- 229910052697 platinum Inorganic materials 0.000 claims 27
- 239000003814 drug Substances 0.000 claims 25
- 229940079593 drug Drugs 0.000 claims 24
- 229930012538 Paclitaxel Natural products 0.000 claims 17
- 229960001592 paclitaxel Drugs 0.000 claims 17
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 17
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 17
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 16
- 229960004316 cisplatin Drugs 0.000 claims 16
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004414 alkyl thio group Chemical group 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000004104 aryloxy group Chemical group 0.000 claims 10
- 230000015572 biosynthetic process Effects 0.000 claims 10
- 150000002431 hydrogen Chemical group 0.000 claims 9
- 230000004936 stimulating effect Effects 0.000 claims 9
- 238000003786 synthesis reaction Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 208000009956 adenocarcinoma Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 210000004072 lung Anatomy 0.000 claims 8
- 201000005202 lung cancer Diseases 0.000 claims 8
- 201000005296 lung carcinoma Diseases 0.000 claims 8
- 208000020816 lung neoplasm Diseases 0.000 claims 8
- 230000004083 survival effect Effects 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 230000006870 function Effects 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 6
- 206010061309 Neoplasm progression Diseases 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims 5
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 208000007502 anemia Diseases 0.000 claims 5
- 125000005110 aryl thio group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims 5
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 239000011593 sulfur Substances 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000004001 thioalkyl group Chemical group 0.000 claims 5
- 230000005751 tumor progression Effects 0.000 claims 5
- 230000000157 blood function Effects 0.000 claims 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims 4
- 230000010437 erythropoiesis Effects 0.000 claims 4
- 150000004677 hydrates Chemical class 0.000 claims 4
- 210000000130 stem cell Anatomy 0.000 claims 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 3
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 2
- 150000003863 ammonium salts Chemical class 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 230000013632 homeostatic process Effects 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 159000000003 magnesium salts Chemical class 0.000 claims 2
- 150000002696 manganese Chemical class 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 230000001766 physiological effect Effects 0.000 claims 2
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 229960005399 satraplatin Drugs 0.000 claims 2
- 190014017285 satraplatin Chemical compound 0.000 claims 2
- KBFJUSPXGQWLBO-UHFFFAOYSA-N sodium;2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound [Na].[Na].OS(=O)(=O)CCSSCCS(O)(=O)=O KBFJUSPXGQWLBO-UHFFFAOYSA-N 0.000 claims 2
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940044684 anti-microtubule agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000004820 blood count Methods 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 238000009583 bone marrow aspiration Methods 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- 150000003883 epothilone derivatives Chemical class 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 230000000913 erythropoietic effect Effects 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- QPUSANCBJDDXSA-UHFFFAOYSA-N ethanethiol;sodium Chemical compound [Na].CCS QPUSANCBJDDXSA-UHFFFAOYSA-N 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 230000003284 homeostatic effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 claims 1
- 108700027936 paclitaxel poliglumex Proteins 0.000 claims 1
- 230000007180 physiological regulation Effects 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000002212 purine nucleoside Substances 0.000 claims 1
- 239000002718 pyrimidine nucleoside Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- PYTISYCTLQTCTM-UHFFFAOYSA-N sodium;2-sulfanylethanesulfonic acid Chemical compound [Na].OS(=O)(=O)CCS PYTISYCTLQTCTM-UHFFFAOYSA-N 0.000 claims 1
- 150000004579 taxol derivatives Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 230000007306 turnover Effects 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/003405 WO2009113983A1 (en) | 2008-03-14 | 2008-03-14 | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011514355A JP2011514355A (ja) | 2011-05-06 |
| JP2011514355A5 true JP2011514355A5 (enExample) | 2011-06-16 |
| JP5694782B2 JP5694782B2 (ja) | 2015-04-01 |
Family
ID=41065492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550647A Active JP5694782B2 (ja) | 2008-03-14 | 2008-03-14 | 肺癌、腺癌及び他の病状のための治療方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2249825B1 (enExample) |
| JP (1) | JP5694782B2 (enExample) |
| AU (1) | AU2008352597B2 (enExample) |
| CA (1) | CA2717181C (enExample) |
| DK (1) | DK2249825T3 (enExample) |
| WO (1) | WO2009113983A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11471431B2 (en) * | 2010-09-16 | 2022-10-18 | Lantern Pharma Inc. | Increasing cancer patient survival time by administration of dithio-containing compounds |
| CN109619552A (zh) * | 2018-12-05 | 2019-04-16 | 贾志丹 | 适用于肿瘤患者的营养治疗型配方及制备方法、用途 |
| AU2020235823A1 (en) * | 2019-03-08 | 2021-11-04 | Lantern Pharma Inc. | Method for treating female non-smokers with non-small cell lung cancer |
| CN115040549A (zh) * | 2022-06-07 | 2022-09-13 | 广东特芯生物科技有限公司 | 一种用于肿瘤的组合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4177263A (en) | 1972-02-28 | 1979-12-04 | Research Corporation | Anti-animal tumor method |
| US4657927A (en) | 1978-05-04 | 1987-04-14 | Research Corporation | Malonato platinum compounds |
| US4310515A (en) | 1978-05-30 | 1982-01-12 | Bristol-Myers Company | Pharmaceutical compositions of cisplatin |
| US4302446A (en) | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| US4451447A (en) | 1980-03-31 | 1984-05-29 | Bristol-Myers Company | Pharmaceutical formulations |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US4915956A (en) | 1987-12-16 | 1990-04-10 | Lyphomed, Inc. | Liquid cisplatin formulations |
| US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
| US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| JPH0776230B2 (ja) | 1992-01-13 | 1995-08-16 | 田中貴金属工業株式会社 | 白金化合物の製造方法 |
| JP2673331B2 (ja) | 1993-01-12 | 1997-11-05 | 田中貴金属工業 株式会社 | 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼） |
| CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| JP3025602B2 (ja) | 1993-05-21 | 2000-03-27 | デビオファーム エス．アー． | 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法 |
| KR100365171B1 (ko) | 1994-08-08 | 2003-02-19 | 드바이오팜 에스.아. | 약학적으로안정한옥살리플라티늄제제 |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| DE19617802A1 (de) | 1996-05-03 | 1997-11-06 | Basf Ag | Verfahren zur heterogen katalysierten Herstellung von Hydroxyalkyl-substituierten Aminoalkinen |
| US6037336A (en) | 1996-09-23 | 2000-03-14 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
| CA2263166C (en) * | 1996-09-23 | 2006-12-12 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
| US6160167A (en) | 1998-04-21 | 2000-12-12 | Bionumerik Pharmaceuticals, Inc. | Mercaptans and disulfides |
| JP2004523518A (ja) * | 2001-01-19 | 2004-08-05 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | より効能が大きく副作用の少ない癌治療方法 |
| US6504049B1 (en) | 2002-04-30 | 2003-01-07 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing pharmaceutically active disulfide salts |
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US20050256055A1 (en) | 2004-05-12 | 2005-11-17 | Hausheer Frederick H | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| WO2007109184A2 (en) * | 2006-03-16 | 2007-09-27 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
| JP6516187B2 (ja) | 2015-07-23 | 2019-05-22 | パナソニックＩｐマネジメント株式会社 | 眠気判定装置、眠気判定方法、眠気判定プログラムおよび記録媒体 |
-
2008
- 2008-03-14 EP EP08726839.7A patent/EP2249825B1/en active Active
- 2008-03-14 WO PCT/US2008/003405 patent/WO2009113983A1/en not_active Ceased
- 2008-03-14 CA CA2717181A patent/CA2717181C/en active Active
- 2008-03-14 JP JP2010550647A patent/JP5694782B2/ja active Active
- 2008-03-14 AU AU2008352597A patent/AU2008352597B2/en active Active
- 2008-03-14 DK DK08726839.7T patent/DK2249825T3/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2786756B1 (en) | Combination therapy with a topoisomerase inhibitor | |
| RU2587013C2 (ru) | Комбинированная химиотерапия | |
| ES2213922T3 (es) | Formulaciones y metodos para reducir la toxicidad de agentes antineoplasticos. | |
| ES2702911T3 (es) | Agente antitumoral que incluye una baja dosis de clorhidrato de irinotecán hidratado | |
| AU2001252442A1 (en) | Combination chemotherapy | |
| WO2010086964A1 (ja) | がん治療のための併用療法 | |
| JP2011514355A5 (enExample) | ||
| CA2648945A1 (en) | Chemoprotective methods and compositions | |
| US6355628B1 (en) | Combination therapy using pentafluorobenzenesulfonamides | |
| ES2278702T3 (es) | Composicion para el tratamiento de metastasis o del cancer, que contiene fluorouracilo y un agente de transferencia de metilol. | |
| MXPA04006822A (es) | Combinaciones que comprenden epotilonas y anti-metabolitos. | |
| JP2009292837A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| US6822001B2 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| JP2011514356A5 (enExample) | ||
| RU2284818C2 (ru) | Комбинированная химиотерапия | |
| KR20150136073A (ko) | 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| JP5581200B2 (ja) | シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤 | |
| HK1202423B (en) | Combination therapy with a topoisomerase inhibitor | |
| NZ740252B2 (en) | Antitumor agent including low-dose irinotecan hydrochloride hydrate | |
| HK1202419B (en) | Combination therapy with a mitotic inhibitor | |
| HK1116409A (en) | Combination chemotherapy | |
| TW201313225A (zh) | 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及順鉑（ｃｉｓｐｌａｔｉｎ）之抗腫瘤組合 | |
| NZ740252A (en) | Antitumor agent including low-dose irinotecan hydrochloride hydrate |